Webinars

AUG 31, 2022 12:00 PM PDT

Welcome Back: How to Address the Decline in HPV Vaccination and Cervical Screening Rates

Sponsored by: Roche Diagnostics

11

Speakers

David T. Pride, MD, PhD

Associate Professor of Pathology, Director of Molecular Microbiology, Associate Director of Microbiology, University of California, San Diego
BIOGRAPHY
William A. Calo, PhD, JD, MPH

Assistant Professor in the Department of Public Health Sciences at the Penn State College of Medicine (PSCOM)
BIOGRAPHY

Event Date & Time

Date: August 31, 2022

Time: 12:00pm (PDT), 3:00pm (EDT), 9:00pm (CEST)

Abstract

Human papillomavirus (HPV) is responsible for more than 99% of cervical cancers. Most HPV infections are transient and are resolved by our immune system, however, persistent infections can cause cervical cancer in individuals with a cervix. Infection is extremely common and most sexually-active individuals (4 in 5) will be exposed to HPV by the age of 50. Vaccination and routine screening can prevent most HPV infections and cervical cancer cases thereby eliminating HPV-caused cervical cancers in the United States.

Learning Objectives

Explain the history and evolution of cervical cancer screening
Examine the HPV vaccination landscape and access to all populations
Examine the impact of access to testing on the development of cervical cancer, with a focus on the COVID-19 pandemic

Webinars will be available for unlimited on-demand viewing after live event.

You May Also Like

Loading Comments...

Content Tags

Attendees